Health
One Bavarian Nordic Shot 58% Effective Against Mpox, Study Shows
- Study was conducted in Canada for about four months in 2022
- High vaccine coverage may blunt mpox rebound, scientists say
A health worker administers a dose of the Bavarian Nordic A/S Jynneos vaccine in West Hollywood, California, in 2022.
Photographer: Jill Connelly/BloombergThis article is for subscribers only.
Bavarian Nordic A/S’s smallpox vaccine was moderately effective in preventing mpox infection after a single dose, according to a study in Ontario, Canada, where the shot probably helped curb a 2022 outbreak.
One vaccination provided about 58% protection against mpox infection, researchers found in the study. It was conducted from mid-June to late October 2022 among gay and bisexual men — the group most affected during a global outbreak sparked by the clade IIb strain of the monkeypox virus.